H.C. Wainwright Adds Fifth Senior Analyst to Its Biotechnology Equity Research Team
February 9, 2015 | New York City, NY
H.C. Wainwright & Co., LLC (“HCW”) announced today that Yi Chen, Ph.D. has joined the firm as a Managing Director in Equity Research and Senior Biotechnology Analyst.
Mr. Chen joins HCW from Aegis Capital Corp. where he was a Senior Equity Research Analyst covering the biotechnology and specialty pharma sectors. Prior to that, he was an Equity Research Associate at Morgan Joseph TriArtisan.
Mr. Chen becomes the fifth Senior Biotechnology Analyst at HCW, which team already includes Andrew Fein, Reni Benjamin, Ph.D., Swayampakula Ramakanth, Ph.D. and Ching-Yi Lin.
“We are excited that Yi has decided to join the Biotechnology Research team at HCW” commented Mark Viklund, Chief Executive Officer of HCW. “His addition strengthens our ability to uncover unique investment opportunities that exist in early stage biotechnology companies.”
About H.C. Wainwright & Co., LLC
H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H.C. Wainwright was established in 1868 and is headquartered in New York City.
H.C. Wainwright & Co., LLC
Mark Viklund, 212-356-0500